Cathodal Transcranial Direct Current Stimulation in Patients With Drug-resistant Focal Epilepsy
NCT ID: NCT05951244
Last Updated: 2023-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2023-04-03
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Personnalized Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epileptic
NCT06334952
Safety and Therapeutic Measures of Tdcs in Patients With Refractory Focal Epilepsy
NCT02866240
Extreme Capsule Electrical Stimulation for Drug-resistant Focal Epilepsy
NCT06663124
High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Refractory Epilepsy
NCT06241963
A Controlled Clinical Trial of Cathodal Transcranial Direct Current Stimulation in Patients With Refractory Epilepsy
NCT01763294
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Transcranial Direct Stimulation
20 epilepsy patients who were eligible and gave consent according to the inclusion criteria. For active group, tDCS treatment will be 2 mA current strength for 30 minutes.
Transcranial Direct Current Stimulation-TessaNova (Teknofil-Turkiye)
Sponge electrodes 5 x 7 cm in size will be used for tDCS application. The sponge electrodes will be wetted with saline and the cathode electrode will be placed on the seizure focus determined by EEG recording and seizure clinic, while the anode electrode will be placed on the contralateral shoulder-deltoid muscle.
Sham-Transcranial Direct Current Stimulation
20 epilepsy patients who were eligible and gave consent according to the inclusion criteria.
For the sham group, the current will increase to 2mA in 10 seconds, continue for the 30s, then decrease to 0 in 10 seconds and cut off.
Transcranial Direct Current Stimulation-TessaNova (Teknofil-Turkiye)
Sponge electrodes 5 x 7 cm in size will be used for tDCS application. The sponge electrodes will be wetted with saline and the cathode electrode will be placed on the seizure focus determined by EEG recording and seizure clinic, while the anode electrode will be placed on the contralateral shoulder-deltoid muscle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transcranial Direct Current Stimulation-TessaNova (Teknofil-Turkiye)
Sponge electrodes 5 x 7 cm in size will be used for tDCS application. The sponge electrodes will be wetted with saline and the cathode electrode will be placed on the seizure focus determined by EEG recording and seizure clinic, while the anode electrode will be placed on the contralateral shoulder-deltoid muscle.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with focal epilepsy with epileptic focus determined according to clinical and electroencephalogram recordings, who have undergone epilepsy surgery but seizures persist, who refuse epilepsy surgery or who are considered unsuitable for surgery,
* Patients who comply with the definition of drug-resistant epilepsy according to ILAE (International League Against Epilepsy Classification) criteria (Patients who have failed to achieve long-term seizure-free status despite at least two appropriate antiepileptic drugs given alone or in combination),
* Minimum 1 or more seizures per month (minimum 3 months),
* No antiepileptic dose change until 3 weeks before the study, stable treatment, and no dose change planned during the study,
* At least 1.5 Tesla MR imaging was performed before the study,
* Signed the informed consent form or the consent form signed by the legal representative,
* EEG was present before the study and all EEG data was accessible,
* Cooperative patients who can speak, understand and communicate in Turkish will be recruited.
Exclusion Criteria
* Detection of more than one seizure focus in the patient,
* The patient had a psychogenic non-epileptic seizure attack (Psychogenic Non-epileptic Seizures -PNES) within 2 years prior to the study,
* Having a generalized onset seizure,
* Having had status epilepticus in the last 1 year,
* Presence of any disease, medical condition, or physical condition that, according to the researchers, could prevent, limit, affect or reduce the subject's completion of a minimum period of 1 + 12 weeks,
* Tissue damage (eczema, etc.) in the area where tDCS will be applied on the skin,
* Patients who are pregnant and do not use/do not want to use contraception during the study period,
* Lactating women,
* Metal implants, fillings in the head or teeth, presence of a medical device in the body (pacemaker, deep brain stimulator, cochlear implant, nerve stimulator, etc.)
* Presence of a skull defect with a radius of 5 mm and/or larger remaining from previous surgeries,
* The patient is participating in another clinical trial.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Koç University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ezgi Tuna Erdoğan, Assist Prof.
Role: PRINCIPAL_INVESTIGATOR
Koç University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Koc University
Istanbul, Sarıyer, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NM002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.